Ryan Crowe
Investor Relations Contact chez REGENERON PHARMACEUTICALS, INC.
Profil
Ryan Crowe is currently the Head of Investor Relations at Regeneron Pharmaceuticals, Inc. Prior to this, he worked as the Senior Director of Investor Relations at Pfizer Inc. and as the Vice President of Investor Relations at Myovant Sciences Ltd.
He received his undergraduate degree from Drexel University and his MBA from The Leonard N Stern School of Business.
Postes actifs de Ryan Crowe
| Sociétés | Poste | Début |
|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Anciens postes connus de Ryan Crowe
| Sociétés | Poste | Fin |
|---|---|---|
| MYOVANT SCIENCES LTD. | Investor Relations Contact | - |
| PFIZER, INC. | Public Communications Contact | - |
Formation de Ryan Crowe
| Drexel University | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
